Microbiome medicine accelerated by new partnership between BiomeBank and Hudson Institute

• BiomeBank and Hudson Institute sign a 4-year collaboration agreement to discover and develop microbial therapies. • BiomeBank gains exclusive license to paediatric IBD study, which identified key bacteria believed to be involved in disease onset and resolution. These bacteria were identified using a world-first method that unlocks culturing and metagenomics of colon biopsy samples. The…

0 Comments

BiomeBank appoints ex-Ellerston Capital CIO and Blackrock North Asia Director as Chair to accelerate commercialisation strategy

BiomeBank appoints Mr Chris Hall as Chair, effective 17 January 2022. Mr Hall brings over 30 years’ experience and impressive track record of investment management across both public and private markets within APAC. BiomeBank’s Series A funding round anticipated to close in early 2022. Formal Therapeutic Goods Association (“TGA”) approval of…

0 Comments